SCHEMBL10041817

SCHEMBL10041817

C=CCc1cccc(C=N)c1C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.44
GABRB2 P47870 2/20 0.44
KMT2A Q03164 7/20 0.42
MEN1 O00255 6/20 0.42
AKR1B1 P15121 1/20 0.38
LMNA P02545 4/20 0.38
GAA P10253 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 5/20 0.35
KDM4E B2RXH2 2/20 0.35
CASP1 P29466 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALOX12 P18054 1/20 0.35
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
PKM P14618 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL627746 0.86 GABRA1 (0.46) GABRA1GABRB2KMT2AMEN1AKR1B1
SCHEMBL22355711 0.83 GABRA1 (0.54) GABRA1GABRB2KMT2AMEN1AKR1B1
SCHEMBL7911646 0.79 GABRA1 (0.45) GABRA1GABRB2KMT2AMEN1AKR1B1
SCHEMBL1733365 0.78 GABRA1 (0.48) GABRA1GABRB2KMT2AMEN1AKR1B1
SCHEMBL170383 0.78 GABRA1 (0.48) GABRA1GABRB2KMT2AMEN1AKR1B1
SCHEMBL10041813 0.77 GABRA1 (0.63) GABRA1GABRB2KMT2AMEN1AKR1B1
SCHEMBL10071057 0.77 CYP3A4 (0.43) GABRA1GABRB2KMT2AMEN1AKR1B1
Ammonia Solution, Strong SCHEMBL8756176 0.76 GABRA1 (0.47) GABRA1GABRB2KMT2AMEN1AKR1B1
SCHEMBL10664862 0.76 GABRA1 (0.47) GABRA1GABRB2KMT2AMEN1AKR1B1
Hydrochloric Acid SCHEMBL28962287 0.76 GABRA1 (0.47) GABRA1GABRB2KMT2AMEN1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643960-B2 Procaspase activating compounds THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-05-09 US disclosed
US-20150344452-A1 PROCASPASE ACTIVATING COMPOUNDS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2015-12-03 US disclosed
US-9102661-B2 Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs THE BOARD OF TRUSTEES OF THE UNIVERSITY ILLINOIS (US) 2015-08-11 US disclosed
US-20140315915-A1 DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-10-23 US disclosed
US-8778945-B2 Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-07-15 US disclosed
US-20120040995-A1 DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344452-A1 PROCASPASE ACTIVATING COMPOUNDS CASP3, CASP6, BAX GABRA1 4262/4885GABRB2 3669/4885KMT2A 3165/4885
US-20140315915-A1 DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS CASP3, CASP6, CASP14 GABRA1 3738/4885GABRB2 3610/4885KMT2A 3466/4885
US-20120040995-A1 DESIGN, SYNTHESIS AND EVALUATION OF PROCASPASE ACTIVATING COMPOUNDS AS PERSONALIZED ANTI-CANCER DRUGS CASP3, CASP6, CASP14 GABRA1 3738/4885GABRB2 3610/4885KMT2A 3466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.